Kazia Therapeutics Files 6-K on Staff Determination Letter
Ticker: KZIA · Form: 6-K · Filed: Dec 19, 2025 · CIK: 1075880
Sentiment: neutral
Topics: regulatory-update, foreign-private-issuer
TL;DR
Kazia Therapeutics filed a 6-K on Dec 19, 2025, referencing a Nov 12, 2025 staff determination letter.
AI Summary
Kazia Therapeutics Limited filed a Form 6-K on December 19, 2025, reporting on a staff determination letter received on November 12, 2025. The filing is for the month of December 2025 and provides information as a foreign private issuer.
Why It Matters
This filing provides an update on regulatory communications for Kazia Therapeutics, which could impact the development and approval timeline of their therapeutic candidates.
Risk Assessment
Risk Level: low — This is a routine filing providing an update on a previously disclosed event, with no new material financial or operational information presented.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- November 12, 2025 (date) — Date of Staff Determination Letter
- December 19, 2025 (date) — Filing Date
FAQ
What is the nature of the staff determination letter received by Kazia Therapeutics?
The filing states that Kazia Therapeutics received a staff determination letter on November 12, 2025, but does not detail its specific content.
What is the purpose of this Form 6-K filing?
The Form 6-K is filed to report information that Kazia Therapeutics Limited is required to disclose to its security holders pursuant to the laws of its home country or that it has made or intends to make public.
When was Kazia Therapeutics Limited incorporated or established?
The filing indicates the company's fiscal year ends on June 30, and it was formerly known as Novogen Ltd, with a name change date of December 28, 1998.
Where is Kazia Therapeutics Limited's principal executive office located?
The principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000, Australia.
Does Kazia Therapeutics file annual reports under Form 20-F or Form 40-F?
Kazia Therapeutics indicates it files annual reports under cover of Form 20-F.
Filing Stats: 357 words · 1 min read · ~1 pages · Grade level 16.5 · Accepted 2025-12-19 16:01:31
Key Financial Figures
- $35 million — ot regained compliance with the minimum $35 million Market Value of Listed Securities requi
- $2.5 million — isting Rule 5550(b)(1), the alternative $2.5 million minimum stockholders' equity requiremen
Filing Documents
- d328722d6k.htm (6-K) — 9KB
- 0001193125-25-326779.txt ( ) — 10KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant's name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F INFORMATION CONTAINED IN THIS FORM 6-K REPORT As previously disclosed, on November 12, 2025, Kazia Therapeutics Limited (the "Company") received a staff determination letter (the "Staff Letter") from the Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company had not regained compliance with the minimum $35 million Market Value of Listed Securities requirement pursuant to Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement") by November 10, 2025. Pursuant to the Nasdaq listing rules and the Staff Letter, unless the Company timely requested a hearing before the Hearings Panel (the "Panel"), the Company's securities would be subject to suspension/delisting. The Company timely requested a hearing before the Panel, which was scheduled for January 8, 2026. On December 18, 2025, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that it has regained compliance with Listing Rule 5550(b)(1), the alternative $2.5 million minimum stockholders' equity requirement to the MVLS Requirement, and that the Company is in compliance with all the applicable listing standards. Accordingly, the hearing was considered moot and cancelled, and Nasdaq has determined to continue the listing of the Company's ADSs on The Nasdaq Capital Market. The Company hereby incorporates by reference the information contained herein into the Company's registration statement on Form F-3 (File No. 333-281937). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend Name: John Friend Title: Chief Executive Officer Date: December 19, 2025